Roth Capital Maintains Buy On Peregrine Pharma Following F2Q15 Results
In a research report released Thursday, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Peregrine Pharma (NASDAQ:PPHM) with a $5 price target, following the company’s fiscal second-quarter, posting EPS of ($0.07) compared to Roth’s estimate of ($0.08).
Pantginis noted, “We are encouraged by the continued progress in SUNRISE enrollment as well as by management efforts to expand bavituximab’s profile. As SUNRISE continues to enroll patients at over 150 global centers, we look forward to what is shaping up to be a data-driven 2015 with catalysts from multiple ISTs in hepatocellular carcinoma, NSCLC, breast cancer, melanoma and rectal adenocarcinoma. We believe that data from the Phase Ib of bavituximab with ipilimumab in melanoma will garner interest and increase visibility.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joseph Pantginis has a total average return of -0.8% and a 45.7% success rate. Pantginis has a -26.1% average return when recommending PPHM, and is ranked #2767 out of 3408 analysts.